Next Article in Journal
Zinc Finger E-Box Binding Homeobox 2 as a Prognostic Biomarker in Various Cancers and Its Correlation with Infiltrating Immune Cells in Ovarian Cancer
Previous Article in Journal
MicroRNA-1270 Inhibits Cell Proliferation, Migration, and Invasion via Targeting IRF8 in Osteoblast-like Cell Lines
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
CIMB
Volume 44
Issue 3
10.3390/cimb44030078
cimb-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Alternate Causes for Pathogenesis of Exfoliation Glaucoma, a Multifactorial Elastotic Disorder: A Literature Review

by
Munmun Chakraborty
1,2 and
Aparna Rao
1,2,*
1
Hyderabad Eye Research Foundation (HERF), L.V. Prasad Eye Institute, Bhubaneswar 751024, Odisha, India
2
School of Biotechnology, KIIT University, Bhubaneswar 751024, Odisha, India
*
Author to whom correspondence should be addressed.
Curr. Issues Mol. Biol. 2022, 44(3), 1191-1202; https://doi.org/10.3390/cimb44030078
Submission received: 8 January 2022 / Revised: 17 February 2022 / Accepted: 19 February 2022 / Published: 1 March 2022
(This article belongs to the Section Molecular Medicine)
Browse Figure
Versions Notes

Abstract

:
Exfoliation glaucoma (XFG) is the most recognizable form of secondary open-angle glaucoma associated with a high risk of blindness. This disease is characterized by white flaky granular deposits in the anterior chamber that leads to the elevation of intraocular pressure (IOP) and subsequent glaucomatous optic nerve damage. Conventionally, XFG is known to respond poorly to medical therapy, and surgical intervention is the only management option in most cases. Various genetic and nongenetic factors are known to be linked to the development of XFG. Despite decades of research on the genetic factors in exfoliation syndrome (XFS) by study groups and global consortia involving different ethnic populations, the pathogenesis of XFS and the mechanism of onset of glaucoma still remains an unsolved mystery. The key lies in understanding how the function of a gene (or set of genes) is altered by environmental triggers, along with other molecular events that underlie the key disease attributes, namely, oxidative stress and the disruption of the blood–aqueous barrier (BAB). It remains a challenge to evolve a theory encompassing all factions of molecular events occurring independently or parallelly that determine the disease manifestation (phenotype) or the stage of the disease in the eye (or in any tissue) in exfoliation. Our enhanced understanding of the underlying molecular pathophysiology of XFG, beyond the known genes or polymorphisms involved in the disease, will lead to improved diagnosis and management and the ability to recognize how the environment influences these key events that lead to the disease phenotype or disease progression. This review summarizes the recent observations and discoveries of four key factors that may hold the answers to the non-lysyl oxidase-like 1 (LOXL1) mechanisms behind XFG pathogenesis, namely, the epigenetic factor miRNA, disordered autophagy along with the potential involvement of mitochondrial mutations, and a compromised aqueous–blood barrier.

1. Introduction

Exfoliation glaucoma (XFG) is a severe and progressive type of sight-threatening [1,2] disease, a systemic fibrillopathy, and is one of the most commonly recognizable, clinically unique form of open-angle glaucoma [2,3,4]. Patients with XFG present with more severe optic nerve damage and visual loss at presentation, are refractory to medical treatment, and are associated with a faster rate of progression compared to other forms of primary glaucoma [3,4]. Exfoliation syndrome (XFS) is a unique ocular and systemic disorder characterized by fibrillar exfoliation deposits on ocular structures (Figure 1a,b) and other organs. Though cutting-edge molecular and genetic approaches have provided powerful insights into the genetic and nongenetic factors, the cause and mechanism of the deposit formation and onset of glaucoma in this disease still remains unexplained. A genome-wide association study performed in 2007 by Thorleifsson and coworkers first showed that three single-nucleotide polymorphisms (SNPs) in the lysyl oxidase-like 1 (LOXL1) gene (rs1048661, rs1048661, and rs3825942) are strongly associated with a risk of XFG [5]. Other genes implicated in XFG include calcium voltage-gated channel subunit alpha1 A (CACNA1A),proteasome maturation protein (POMP), transmembrane protein 136 (TMEM136), 1-acylglycerol-3-phosphate O-acyltransferase 1 (AGPAT1), RNA-binding motif single-stranded interacting protein 3 (RBMS3), and semaphorin 6A (SEMA6A) [6,7]. Though several groups have identified several key genes responsible for the disease, the genetic etiology is complicated by the frequent occurrence of LOXL1 SNPs among healthy people, the uncertain role of polymorphisms, and the allele reversal in different ethnic populations [5,6].
Several risk factors have been recognized that predispose people to XFS, including high ambient light, higher temperatures, proximity to the equator, dietary factors such as coffee consumption, and greater exposure to sunlight or outdoor work [8,9]. It is, however, unclear whether these risk factors influence or change the genetic predisposition to XFS or XFG. Further, while oxidative stress is believed to be a key factor in XFS pathogenesis, the precise molecular signaling pathways that are responsible for XFS disease or disease progression to XFG remain unknown.
Transforming growth factor-beta (TGF-β) is a ubiquitous cytokine regulating several key cellular processes, thereby determining cell fate in any tissue. It achieves this by the regulation of downstream matrix metalloproteinases (MMPs) for extracellular matrix (ECM)/collagen homeostasis, cross-talk with other key pathways such as autophagy, fibrosis through Rho-kinases, and gene transcription via canonical and noncanonical pathways (Figure 1c). This is known to be upregulated in eyes with XFS and XFG, though its role in disease pathogenesis in unclear. In our earlier study, we found TGF-β1 to be upregulated in severe glaucoma, though associated with the differential expression of downstream molecules regulating fibrosis or ECM metabolism [10]. Further, this forms an important link for regulating and modulating ECM degradation via MMP9 in XFG, where the activity of the latter is compromised in severe stages despite the continued overexpression of TGF-β1. We also found specific circulatory microRNAs (miRNAs) to be regulating the proteosome clearance–unfolded protein response (UPR) pathway via SMADs, specifically in XFG [10]. TGF-β1 also regulates mitochondrial reactive oxygen species (ROS) production and modulates cell senescence, while oxidative-stress-induced ROS production can cause TGF activation by upstream regulation. Further, stress markers and vascular ischemic events characteristic of XFS may also be regulated by TGF-β1 that regulates vascular endothelial inflammation, which may be the key factor for disrupted blood–aqueous barriers (BAB) in XFS eyes. While genetic factors can cause a predisposition to XFS development or XFG, the role of the above molecular events in precipitating characteristic and well-recognized clinical features in XFS or the onset of glaucoma in these eyes needs an in-depth study.
The purpose of this manuscript is to review the recent and past literature on the pathogenesis and associations of XFG with the less extensively described and studied roles of miRNAs, mitochondrial mutations, altered autophagy, and leaky BABs. An enhanced understanding of the molecular pathophysiology will lead to improved management, diagnosis, and new treatments for glaucoma.

2. Methods

We performed a literature search of the PubMed database, identifying all articles associated with XFG and XFS using the following MeSH terms: exfoliation glaucoma, exfoliation syndrome, autophagy, miRNAs, mitochondria, and blood–aqueous barrier. The selection of articles for the review was based on the following criteria: (i) exfoliation glaucoma OR exfoliation syndrome AND autophagy (n = 290); (ii) exfoliation glaucoma OR exfoliation syndrome AND mitochondria (n = 410); (iii) exfoliation glaucoma OR exfoliation syndrome AND miRNA (n = 292); (iv) exfoliation glaucoma OR exfoliation syndrome AND blood–aqueous barrier (n = 398). After searching and evaluating, all selected papers were independently examined by the two authors (M.C. and A.R.). Those that did not have validation experiments, included mere hypotheses rather than being evidence-based, or were in conflict between two authors were rejected. Finally, after a thorough review, we narrowed down the focus of this review to 83 articles.

3. Potential Role of miRNAs in XFG

MicroRNAs are small, noncoding RNAs, 21–25 nucleotides in length, that regulate gene expression by binding to the 3′-untranslated region (UTR) of specific messenger RNAs (mRNAs) for degradation or translational repression [11,12,13,14,15]. The expression of miRNAs is often typical for a particular tissue or during essential cellular processes [11,12,13,14,15,16]. A single miRNA can modulate the expression of multiple mRNAs that regulate various physiological processes such as hematopoiesis, proliferation, tissue differentiation, cell-type identity maintenance, apoptosis, signal transduction, and organ development by regulating the expression of various genes [16,17,18,19]. They may exist in a stable state within cells or outside cells in biological fluids, including plasma and aqueous humor (AH), vitreous humor, serum, saliva, urine, and tears, and can exist as exosomes or be bound to carrier proteins [20,21]. Previous studies have reported that the expression of miRNAs can be involved in senescence or age-related neurological disorders, diabetes, degenerative arthritis, carcinomas, and cataracts [16,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37]. In glaucoma, miRNAs can regulate ECM metabolism by regulating TGF-β and can regulate stiffness by the accelerated maturation of ECM proteins, altering the trabecular meshwork (TM) contractile properties, thus accelerating or inhibiting TM cell senescence, or by modulating oxidative- and mechanical-stress-induced damage [20,22,38] in the cell/tissue(Table 1). Alterations in the miRNA levels may indicate pathogenic processes underlying disease or a stage transition of the specific disease. Thus, miRNAs serve as valuable noninvasive biomarkers for various diseases and help to prognosticate the severity of diseases that are caused by the modulation of the specific processes that they regulate [15,27].
The role of miRNAs in glaucoma remains unclear, with several studies reporting miRNAs specifically expressed in the AH or serum in eyes with glaucoma [15,21,23,39,40]. Drewry et al. found three miRNAs (miR-125b-5p, miR-302d-3p, and miR-451a) and five miRNAs (miR-122-5p, miR-3144-3p, miR-320a, miR-320e, and miR-630) to be significantly differentially expressed in the AH of primary open-angle glaucoma (POAG) and XFG eyes, respectively, compared to controls [41]. Pathway analysis revealed that these miRNAs are involved in potential glaucoma pathways including tight junctions and TGF-β signaling, all of which are known in XFS pathogenesis. Another study, however, found no difference in miRNA expression between the different kinds of primary glaucoma, though hsa-miR-6722-3p, hsa-miR-184, and hsa-miR-1260b were more frequently found in XFG and POAG, respectively [42]. Another study identified higher levels of expression of 20 miRNAs in XFG and POAG patients than in controls, with 6 out of the 20 miRNAs (miR-637, miR-99b-3p, miR-4725-3p, miR-4724-5p, miR-4358, and miR-433-3p) elevated in both plasma and AH [43]. In our earlier study, we found 12 out of 84 miRNAs to be upregulated in XFG. Out of these 12, 3 miRNAs (hsa-miR-122-5p, hsa-miR-124-3p, and hsa-miR-424-5p) were involved in pathways, namely, TGF-β1, fibrosis/ECM, and proteoglycan metabolism with common effectors such as SMAD3/2 [10]. Phenotype comparisons with fibrosis-related miRNA gave similar results, with hsa-miR-19a-3p and hsa-miR-30a-5p related to proteoglycans being significantly downregulated in ocular hypertension (OHT) compared to XFG. Flaky aggregates are visibly seen deposited on the lenses of XFS/XFG patients. With its monolayer structure and direct exposure to ultraviolet radiation, the lens capsule epithelium is a significant subject for exploring complex elements, including genetics and environmental influences in XFS. Tomczyk-Socha et al. reported the upregulation of miR-125b in the lens capsules of XFS patients when compared to controls (cataract), with no significant upregulation in the XFG patients [44].
It is believed that concentrating on the polymorphisms in the miRNA biogenesis pathway and their dynamic interaction with the genes under specific environmental triggers could uncover data for disease anticipation and pharmacogenomics in XFS [44,45,46]. Recently, various studies have reported differential miRNA expression status in the AH and trabecular meshwork, two anatomical structures that are closely related to glaucoma, and linked them to the apoptosis of retinal ganglion cells and IOP [21,38,39]. Fewer studies, however, have reported polymorphisms in miRNA [45,46,47,48]. One study reported rs1057035 polymorphisms in the 3′-UTR of the DICER gene to be associated with a decreased risk of XFG, and rs55671916 in the 3′-UTR of the exportin 5 (XPO5) gene with an increased risk of XFG [4,47]. As per the miRNASNP database, the polymorphism rs11382316 results in a gain of function of miRNA-3161 in the genes caveolin-1 (CAV1), cytochrome P450 family 1 subfamily B member 1 (CYP1B1), and CACNA1A, and a loss of function of transforming growth factor-beta receptor 3 (TGFBR3). This result seems to further support a previously reported implication of the CACNA1A gene in XFS susceptibility [7].
Given the significance of ECM elements to the ordinary physiology of the outpouring pathway, miRNAs that control ECM metabolism could be reasonable targets to impact AH dynamics in XFS eyes. The best-described group of miRNAs that directs ECM digestion is the miR-29 family, including hsa-miR-29a, hsa-miR-29b, and hsa-miR-29c. In a study by Luna et al., the transfection of TM cells with miR-29b mimic caused the downregulation of various ECM genes, including collagens and fibronectin, as well as the targeting of genes involved in ECM remodeling (SPARC/osteonectin). Interestingly, persistent oxidative stress induced by incubation at 40% oxygen led to a critical downregulation of miR-29b in TM cell lines that were related to an increased expression of several ECM genes [49]. Strategies to elevate miR-29 expression in TM cells may be advantageous to limit ECM deposition, avert cell loss, and maintain normal levels of AH outflow facility. However, this family has not been studied in targeting TM function in XFG eyes, nor has its role in XFS and XFG eyes been identified in any study. Further, the regulation of miRNA biogenesis and the TGF-β pathway in exfoliation remains unexplored. A detailed study in this direction may give insights into how TGF-β-regulated processes are modulated differentially in disease progression or in different ethnic populations.
In summary, studies so far suggest that miRNAs are key regulatory elements that can control the pathophysiology of the outflow pathway and modulate ECM degradation or gene expression in XFS. These can serve as promising biomarkers for disease progression, treatment responders/nonresponders, and effective diagnosis while offering insights into possible therapeutic strategies for XFG. To understand the maximum capacity of miRNAs as helpful targets in XFG, it will be important to work towards filling these lacunae in the future.

4. Autophagy and Mitochondrial Dysfunction and Protein Aggregate Clearance

We recently demonstrated a decreased UPR clearance in XFG compared to earlier forms of the disease associated with increased TGF levels in all disease stages, which suggest the potential regulation of the autophagy pathway and TGF–autophagy cross-talk involved in cell repair and aggregate clearance [50]. Autophagy is an intracellular trafficking system that conveys cytosolic constituents to the lysosome for ensuing degradation, which is crucial for misfolded protein clearance, cell homeostasis by ubiquitin–proteasomal degradation, and cell repair [51,52,53,54,55]. Immunohistochemical and mass spectrometry investigations have uncovered that exfoliative material is a profoundly glycosylated proteinaceous complex that is very impervious to degradation, both inside the body and under experimental conditions [51]. Given the significance of the autophagic clearance of protein aggregates, autophagy-related genes (ATG genes) might be involved in XFG pathology beyond primary glaucoma [53]. Studies have also shown the association of neurodegeneration with mitochondrial dysfunction and abnormal mitophagy [56,57,58]. Impaired mitophagy causes the accumulation of damaged mitochondria that may have a severe impact on acell’s ability to manage oxidative insult and/or ability to clear misfolded proteins, which may be impaired in XFG eyes. A decreased autophagic flux (an indicator of autophagic activity) caused by oxidative stress may be one of the factors that lead to the progressive failure of cellular TM function with age [59,60,61,62,63]. In our earlier study, autophagy genes were abruptly upregulated in severe POAG and primary angle-closure glaucoma (PACG) compared to moderate glaucoma, suggesting the role of autophagy in disease progression [53].
Similar studies on mitochondrial dysfunction and impaired autophagic clearance are sparse in XFS and XFG. A Spanish-based study, evaluating genetic variants in three critical genes of autophagy (ATG16L, ATG2B, and ATG5) in the development of XFS and XFG in a Spanish population, reported no difference in either the genotype distributions or allelic frequencies of the known polymorphisms between XFS/XFG or controls [54]. One study using explant-cultured tenon fibroblasts from XFS and age-matched POAG patients observed 1.38 times bigger fibroblasts that were less organized, and demonstrated a decreased clearance of autophagosomes with abnormal endocytic trafficking in fibroblasts obtained from XFS eyes. This suggested the aberrant autophagic–lysosomal clearance of proteins in XFS eyes [55]. They also reported a higher content of cells with low mitochondrial membrane potential, suggesting impaired mitophagy. Mitochondrial DNA (mtDNA) has a higher prevalence of mutations owing to less-efficient repair systems [55]. The rate of mtDNA mutations is multiple times that of nuclear DNA and is thought to be triggered by ROS formation inside the mitochondria. Although mtDNA encodes only about 1% of the proteins found in mitochondria, it incorporates subunits of oxidative phosphorylation proteins. Izzotti et al. evaluated TM specimens obtained from surgeries of various glaucoma and control patients [59]. They showed that mitochondrial dysfunction induced by oxidative stress is more predominant in POAG and XFG than in other glaucoma forms. XFG specimens had the most elevated levels of mtDNA deletion, oxidative DNA damage, and mitochondrial loss per cell. The mtDNA 4977deletion values seen in XFG were >2 times those recognized in POAG. Studies using advanced whole-mitochondrial sequencing technology have identified 22 mtDNA changes, comprising 7 novel transformations with 36.4% of the mtDNA changes in the complex I mitochondrial gene [60]. One study reported 27 unique novel non-synonymous mtDNA changes in POAG, with 22 changes being potentially pathogenic [61]. Another study reported the absence of any mutation in XFG patients in the various nuclear genes associated with primary glaucoma or in the mitochondrial genome [62,63,64]. Heterozygous optic atrophy type1 (OPA1) is known to influence mitochondrial steadiness and has now been implicated in a few optic neuropathies. It codes for a dynamin-like GTPase protein found in a polymeric structure in the inner mitochondrial membrane that has multiple distinct roles [65,66,67,68], primarily related to maintaining a highly interconnected mitochondrial network. Thomas et al. studied OPA1 mutations in POAG patients and found significantly lower expression levels of OPA1 than in controls. Decreased OPA1 expression, another sign of mitochondrial-actuated apoptosis, may play a part in the advancement of glaucoma in XFS [66]. To test the theory that mitochondrial haplogroups influence the risk of developing glaucoma, a group genotyped 12 single-nucleotide polymorphisms that characterize the European mtDNA haplogroups in controls and two German cohorts with XFG or normal-tension glaucoma. Individuals with haplogroup-U were found to have a lower risk for developing XFG in this study, suggesting mitochondrial dysfunction in XFS pathogenesis [69]. In summary, research related to mitochondrial dysfunction and impaired mitophagy in XFG has been less extensive to date, with very few studies evaluating the role of the environment in triggering the dysregulation of these processes in XFG. There is a compelling need to supplement the existing literature on XFG pathogenesis with functional studies analyzing various populations and different environmental influences on mitochondrial function in XFS/XFG.

5. The Blood–Aqueous Barrier in Eyes with Exfoliation Syndrome

The eye, similar to the brain, is an organ endowed with immune privilege, an attribute conferred by complex ocular barrier systems. Two kinds of barriers have been distinguished inside the eye, each described by its unique tissue restriction, immunologic properties, and physiological capacities, namely, the BAB and the blood–retina barrier (BRB) [70,71]. Eyes with XFS frequently show clinical signs of impairment of the BAB [72]. The breakdown of the BAB is confirmed by an elevation in AH proteins. Mice without the LOXL1 gene, a significant genetic risk factor for XFS and XFG, displayed an increased dispersion of fluorescein at the BAB, indicating the interruption of the ciliary epithelial barrier [73]. Kuchle et al. studied the alteration in the BAB in XFS patients by the histochemical staining of endogenous albumin and reported the impairment of the BAB in XFS that was confined to the iris and, to a lesser extent, may involve the ciliary body [74]. Elevated levels of AH clusterin in XFS, POAG, and XFG cases compared to controls has been reported by several studies [75,76]. Zenkel et al. [77] reasoned that this was due to the disintegration of the BAB and leakage of systemic clusterin into the AH. On the other hand, Doudevski et al. [76] contended that this increase could not be explained by the breakdown of the BAB alone and that local synthesis might therefore play a significant role. Yildirim et al. found that serum interleukine 6 (IL-6) levels were altogether higher in XFS when contrasted with controls, suggesting higher levels of subclinical inflammation and BAB in XFS patients [78]. Kondkar et al. observed that higher plasma tumor necrosis factor alpha (TNF-α) levels might be a marker for the progression of XFS to XFG [79]. What triggers the disruption of BAB in XFS patients is unclear, though some risk factors such as oxidative stress, raised homocysteine, AH nitric oxide (NO), and vascular endothelial growth factor (VEGF) are presumed to play a role. Eraslan et al. revealed high acylated ghrelin/ghrelin proportions in XFG cases and suggested that acylated ghrelin may adversely trigger prostaglandin and NO release in XFG, causing progressive damage [80]. Bleich et al. observed that significantly elevated (twofold) homocysteine levels in the AH and the plasma of XFG patients with aqueous homocysteine was significantly correlated with corresponding plasma levels [81]. VEGF is also known to increase vascular permeability, contributing to disrupted BABs in XFS [82,83]. This may also explain the frequent ischemic systemic associations in XFS patients, including cardiovascular disease, transient ischemic attacks, and vascular occlusive disease. The mean AH and plasma VEGF concentrations and the mean AH NO concentrations were significantly higher in patients with XFG than in controls [82,83,84]. Studies have reported marginally higher mean AH and plasma levels of NO and VEGF in XFG than in patients with XFS, but the differences were not statistically significant. These studies imply a need for further studies on how these factors cause BAB breakdown and precipitate a cascade of protein complex aggregate accumulation over different ocular structures in XFS. It may be worthwhile exploring the role of ambient light and continued TGF-β exposure in the key downstream pathways such as autophagy, the disruption of the BAB, mitochondrial dysfunction, and oxidative stress in the TM cells causing functional damage. Understanding these processes in animal or invitro models would be crucial to identify mechanisms to reverse or dissolve these aggregates and prevent tissue dysfunction in XFG.

6. Conclusions

Vast volumes of genetic studies across the globe have failed to explain the complex mechanisms underlying XFS pathogenesis and the onset of glaucoma in these eyes. It is increasingly becoming clear that molecular processes mediated and regulated by environmental triggers hold the key to these perplexing questions. Current knowledge on the role of miRNA, mitochondrial dysfunction/autophagic clearance, or the disrupted BAB does not explain the reason for the differential involvement of some populations or eyes in XFS or even the onset of glaucoma. This review sums up the current ideas and the gaps existing in these areas in XFS research that may give newer insights and therapeutic targets for XFS. The comprehension of the functional consequences and molecular mechanisms of XFG and the targeting of novel therapeutic approaches are the major roads for future research in XFG pathogenesis.

Author Contributions

Writing—original draft preparation, M.C. and A.R.; writing—review andediting, M.C. and A.R.; funding acquisition, A.R. All authors have read and agreed to the published version of the manuscript.

Funding

This work was funded in full by DBT Wellcome Trust India Alliance, grant ref. number IA/CPHI/15/1/502031, awarded to Dr. Aparna Rao.

Institutional Review Board Statement

The study was approved by the Institutional Review Board (or Ethics Committee) of L.V. PRASAD EYE INSTITUTE (protocol code 2016-60-IM-12 and date of approval 28 May 2019).

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Ritch, R. The management of exfoliative glaucoma. Prog. Brain Res. 2008, 173, 211–224. [Google Scholar]
  2. Ritch, R.; Schlotzer-Schrehardt, U.; Konstas, A.G. Why is glaucoma associated with exfoliation syndrome? Progr. Retin. Eye Res. 2003, 22, 253–275. [Google Scholar] [CrossRef]
  3. Lee, R.K. The molecular pathophysiology of exfoliation glaucoma. Curr. Opin. Ophthalmol. 2008, 19, 95–101. [Google Scholar] [CrossRef] [PubMed]
  4. Jeng, S.M.; Karger, R.A.; Hodge, D.O.; Burke, J.P.; Johnson, D.H.; Good, M.S. The risk of glaucoma in exfoliation syndrome. J. Glaucoma 2007, 16, 117–121. [Google Scholar] [CrossRef] [PubMed]
  5. Thorleifsson, G.; Magnusson, K.P.; Sulem, P.; Walters, G.; Gudbjartsson, D.F.; Stefansson, H.; Jonsson, T.; Jonasdottir, A.; Jonasdottir, A.; Stefansdottir, G.; et al. Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma. Science 2007, 317, 1397–1400. [Google Scholar] [CrossRef] [PubMed]
  6. Aung, T.; Ozaki, M.; Lee, M.C.; Schlötzer-Schrehardt, U.; Thorleifsson, G.; Mizoguchi, T.; Igo, R.P.; Haripriya, A., Jr.; Williams, S.E.; Astakhov, Y.S.; et al. Genetic association study of exfoliation syndrome identifies a protective rare variant at LOXL1 and five new susceptibility loci. Nat. Genet. 2017, 49, 993–1004. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Aung, T.; Ozaki, M.; Mizoguchi, T.; Allingham, R.R.; Li, Z.; Haripriya, A.; Nakano, S.; Uebe, S.; Harder, J.M.; Chan, A.S.; et al. A common variant mapping to CACNA1A is associated with susceptibility to exfoliation syndrome. Nat. Genet. 2015, 47, 387–392. [Google Scholar] [CrossRef] [Green Version]
  8. Dewundara, S.; Pasquale, L.R. Exfoliation syndrome: A disease with an environmental component. Curr. Opin. Ophthalmol. 2015, 26, 78–81. [Google Scholar] [CrossRef]
  9. Ghaffari, S.M.; Damji, K.F.; Unsworth, L.D. Recent advances in risk factors associated with ocular exfoliation syndrome. Acta Ophthalmol. 2020, 98, 113–120. [Google Scholar] [CrossRef]
  10. Rao, A.; Chakraborty, M.; Roy, A.; Sahay, P.; Pradhan, A.; Raj, N. Differential miRNA Expression: Signature for Glaucoma in Exfoliation. Clin. Ophthalmol. 2020, 14, 3025–3038. [Google Scholar] [CrossRef]
  11. Filipowicz, W.; Bhattacharyya, S.N.; Sonenberg, N. Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight? Nat. Rev. Genet. 2008, 9, 102–114. [Google Scholar] [CrossRef]
  12. Chen, K.; Rajewsky, N. The evolution of gene regulation by transcription factors and microRNAs. Nat. Rev. Genet. 2007, 8, 93–103. [Google Scholar] [CrossRef] [PubMed]
  13. Bentwich, I.; Avniel, A.; Karov, Y.; Aharonov, R.; Gilad, S.; Barad, O.; Barzilai, A.; Einat, P.; Einav, U.; Meiri, E.; et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat. Genet. 2005, 37, 766–770. [Google Scholar] [CrossRef] [PubMed]
  14. Nitschke, L.; Tewari, A.; Coffin, S.L.; Xhako, E.; Pang, K.; Gennarino, V.A.; Johnson, J.L.; Blanco, F.A.; Liu, Z.; Zoghbi, H.Y. miR760 regulates ATXN1 levels via interaction with its 5′ untranslated region. Genes Dev. 2020, 34, 1147–1160. [Google Scholar] [CrossRef]
  15. Guo, R.; Shen, W.; Su, C.; Jiang, S.; Wang, J. Relationship between the pathogenesis of glaucoma and miRNA. Ophthalmic Res. 2017, 57, 194–199. [Google Scholar] [CrossRef]
  16. Undi, R.B.; Kandi, R.; Gutti, R.K. MicroRNAs as Haematopoiesis Regulators. Adv. Hematol. 2013, 2013, 695754. [Google Scholar] [CrossRef]
  17. Lu, B.; Christensen, I.T.; Ma, L.W.; Wang, X.L.; Jiang, L.F.; Wang, C.X.; Feng, L.; Zhang, J.S.; Yan, Q.C. miR-24-p53 pathway evoked by oxidative stress promotes lens epithelial cell apoptosis in age-related cataracts. Mol. Med. Rep. 2018, 17, 5021–5028. [Google Scholar] [CrossRef] [Green Version]
  18. Wang, Y.; Li, F.; Wang, S. MicroRNA-93 is overexpressed and induces apoptosis in glaucoma trabecular meshwork cells. Mol. Med. Rep. 2016, 14, 5746–5750. [Google Scholar] [CrossRef] [Green Version]
  19. Jayaram, H.; Cepurna, W.O.; Johnson, E.C.; Morrison, J.C. MicroRNA Expression in the Glaucomatous Retina. Investig. Ophthalmol. Vis. Sci. 2015, 56, 7971–7982. [Google Scholar] [CrossRef] [Green Version]
  20. Weber, J.A.; Baxter, D.H.; Zhang, S.; Huang, D.Y.; How Huang, K.; Jen, L.M.; Galas, D.J.; Wang, K. The microRNA spectrum in 12 body fluids. Clin. Chem. 2010, 56, 1733–1741. [Google Scholar] [CrossRef]
  21. Tanaka, Y.; Tsuda, S.; Kunikata, H.; Sato, J.; Kokubun, T.; Yasuda, M.; Nishiguchi, K.M.; Inada, T.; Nakazawa, T. Profiles of extracellular miRNAs in the aqueous humor of glaucoma patients assessed with a microarray system. Sci. Rep. 2014, 4, 5089. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Lee, Y.H.; Kim, S.Y.; Bae, Y.S. Upregulation of miR-760 and miR-186 is associated with replicative senescence in human lung fibroblast cells. Mol. Cells 2014, 37, 620–627. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Liu, Y.; Chen, Y.; Wang, Y.; Zhang, X.; Gao, K.; Chen, S.; Zhang, X. microRNA profiling in glaucoma eyes with varying degrees of optic neuropathy by using next-generation sequencing. Investig. Ophthalmol. Vis. Sci. 2018, 59, 2955–2966. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Peng, C.H.; Liu, J.H.; Woung, L.C.; Lin, T.J.; Chiou, S.H.; Tseng, P.C.; Du, W.Y.; Cheng, C.K.; Hu, C.C.; Chien, K.H.; et al. MicroRNAs and cataracts: Cor-relation among let-7 expression, age and severity of lens opacity. Br. J. Ophthalmol. 2012, 96, 747–751. [Google Scholar] [CrossRef] [PubMed]
  25. Sand, M.; Gambichler, T.; Sand, D.; Skrygan, M.; Altmeyer, P.; Bechara, F.G. MicroRNAs and the skin: Tiny players in the body’s largest organ. J. Dermatol. Sci. 2009, 53, 169–175. [Google Scholar] [CrossRef]
  26. Khee, S.G.; Yusof, Y.A.; Makpol, S. Expression of senescence-associated microRNAs and target genes in cellular aging and modulation by tocotrienol-rich fraction. Oxidative Med. Cell. Longev. 2014, 2014, 725929. [Google Scholar]
  27. Kim, J.; Yoon, H.; Chung, D.E.; Brown, J.L.; Belmonte, K.C.; Kim, J. miR-186 is decreased in aged brain and suppresses BACE 1 expression. J. Neurochem. 2016, 137, 436–445. [Google Scholar] [CrossRef] [Green Version]
  28. Lou, G.; Xu, W.; Dong, F.; Chen, G.; Liu, Y. Plasma miR-17, miR-20a, miR-20b and miR-122 as potential biomarkers for diagnosis of NAFLD in type 2 diabetes mellitus patients. Life Sci. 2018, 208, 201–207. [Google Scholar]
  29. Xiu, C.; Jiang, J.; Song, R. Expression of miR-34a in cataract rats and its related mechanism. Exp. Ther. Med. 2020, 19, 1051–1057. [Google Scholar] [CrossRef] [Green Version]
  30. Pan, Y.J.; Wei, L.L.; Wu, X.J.; Huo, F.C.; Mou, J.; Pei, D.S. MiR-106a-5p inhibits the cell migration and invasion of renal cell carcinoma through targeting PAK5. Cell Death Dis. 2017, 8, e3155. [Google Scholar] [CrossRef]
  31. Que, T.; Song, Y.; Liu, Z.; Zheng, S.; Long, H.; Li, Z.; Liu, Y.; Wang, G.; Liu, Y.; Zhou, J.; et al. Decreased miRNA-637 is an unfavorable prognosis marker and promotes glioma cell growth; migration and invasion via direct targeting Akt1. Oncogene 2015, 34, 4952–4963. [Google Scholar] [CrossRef] [PubMed]
  32. Shi, X.B.; Xue, L.; Yang, J.; Ma, A.H.; Zhao, J.; Xu, M.; Tepper, C.G.; Evans, C.P.; Kung, H.J.; deVere White, R.W. An androgen-regulated miRNA suppresses Bak1 expression and induces BACE1 expression. J. Neurochem. 2016, 137, 436–445. [Google Scholar]
  33. Ye, D.; Zhang, T. Androgen-independent growth of pros-tate cancer cells. Proc. Natl. Acad. Sci. USA 2007, 104, 19983–19988. [Google Scholar]
  34. Thomson, J.M.; Newman, M.; Parker, J.S.; Morin-Kensicki, E.M.; Wright, T.; Hammond, S.M. Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev. 2006, 20, 2202–2207. [Google Scholar] [CrossRef] [Green Version]
  35. Xu, J.; Li, J.; Zheng, T.H.; Bai, L.; Liu, Z.J. MicroRNAs in the occurrence and development of primary hepatocellular carcinoma. Adv. Clin. Exp. Med. 2016, 25, 971–975. [Google Scholar] [CrossRef] [Green Version]
  36. Zhang, J.F.; He, M.L.; Fu, W.M.; Wang, H.; Chen, L.Z.; Zhu, X.; Chen, Y.; Xie, D.; Lai, P.; Chen, G.; et al. Primate-specific microRNA-637 inhibits tumorigenesis in hepatocellular carcinoma by disrupting signal transducer and activator of transcription 3 signaling. Hepatology 2011, 54, 2137–2148. [Google Scholar] [CrossRef] [PubMed]
  37. Zhang, J.F.; Fu, W.M.; He, M.L.; Wang, H.; Wang, W.M.; Yu, S.C.; Bian, X.W.; Zhou, J.; Lin, M.C.; Lu, G.; et al. MiR-637 maintains the balance between adipocytes and osteoblasts by directly targeting Osterix. Mol. Biol. Cell 2011, 22, 3955–3961. [Google Scholar] [CrossRef] [Green Version]
  38. Youngblood, H.; Cai, J.; Drewry, M.D.; Helwa, I.; Hu, E.; Liu, S.; Yu, H.; Mu, H.; Hu, Y.; Perkumas, K.; et al. Expression of mRNAs; miRNAs; and lncRNAs in Human Trabecular Meshwork Cells Upon Mechanical Stretch. Investig. Ophthalmol. Vis. Sci. 2020, 61, 2. [Google Scholar] [CrossRef] [PubMed]
  39. Jayaram, H.; Phillips, J.I.; Lozano, D.C.; Choe, T.E.; Cepurna, W.O.; Johnson, E.C.; Morrison, J.C.; Gattey, D.M.; Saugstad, J.A.; Keller, K.E. Comparison of MicroRNA expression in aqueous humor of normal and primary open-angle glaucoma patients using PCR arrays: A pilot study. Investig. Ophthalmol. Vis. Sci. 2017, 58, 2884–2890. [Google Scholar] [CrossRef] [Green Version]
  40. Li, X.; Zhao, F.; Xin, M.; Li, G.; Luna, C.; Li, G.; Zhou, Q.; He, Y.; Yu, B.; Olson, E.; et al. Regulation of intraocular pressure by microRNA cluster miR-143/145. Sci. Rep. 2017, 7, 915. [Google Scholar] [CrossRef]
  41. Drewry, M.D.; Challa, P.; Kuchtey, J.G.; Navarro, I.; Helwa, I.; Hu, Y.; Mu, H.; Stamer, W.D.; Kuchtey, R.W.; Liu, Y. Differentially expressed microRNAs in the aqueous humor of patients with exfoliation glaucoma or primary open-angle glaucoma. Hum. Mol. Genet. 2018, 27, 1263–1275. [Google Scholar] [CrossRef] [PubMed]
  42. Kosior-Jarecka, E.; Czop, M.; Gasińska, K.; Wróbel-Dudzińska, D.; Zalewski, D.P.; Bogucka-Kocka, A.; Kocki, J.; Żarnowski, T. MicroRNAs in the aqueous humor of patients with different types of glaucoma. Graefe’s Arch. Clin. Exp. Ophthalmol. 2021, 259, 2337–2349. [Google Scholar] [CrossRef] [PubMed]
  43. Hindle, A.G.; Thoonen, R.; Jasien, J.V.; Grange, R.M.H.; Amin, K.; Wise, J.; Ozaki, M.; Ritch, R.; Malhotra, R.; Buys, E.S. Identification of Candidate miRNA Biomarkers for Glaucoma. Investig. Ophthalmol. Vis. Sci. 2019, 60, 134–146. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Tomczyk-Socha, M.; Baczyńska, D.; Przeździecka-Dołyk, J.; Turno-Kręcicka, A. MicroRNA-125b overexpression in exfoliation syndrome. Adv. Clin. Exp. Med. Off. Organ Wroc. Med. Univ. 2020, 29, 1399–1405. [Google Scholar] [CrossRef] [PubMed]
  45. Moschos, M.M.; Dettoraki, M.; Karekla, A.; Lamprinakis, I.; Damaskos, C.; Gouliopoulos, N.; Tibilis, M.; Gazouli, M. Polymorphism analysis of miR182 and CDKN2B genes in Greek patients with primary open angle glaucoma. PLoS ONE 2020, 15, e0233692. [Google Scholar] [CrossRef]
  46. He, J.; Zhao, J.; Zhu, W.; Qi, D.; Wang, L.; Sun, J.; Wang, B.; Ma, X.; Dai, Q.; Yu, X. MicroRNA biogenesis pathway genes polymorphisms and cancer risk: A systematic review and meta-analysis. PeerJ 2016, 4, e2706. [Google Scholar] [CrossRef] [Green Version]
  47. Chatzikyriakidou, A.; Founti, P.; Melidou, A.; Minti, F.; Bouras, E.; Anastasopoulos, E.; Pappas, T.; Haidich, A.B.; Lambropoulos, A.; Topouzis, F. MicroRNA-related polymorphisms in exfoliation syndrome; pseudoexfoliative glaucoma; and primary open-angle glaucoma. Ophthalmic Genet. 2018, 39, 603–609. [Google Scholar] [CrossRef]
  48. Saeki, M.; Watanabe, M.; Inoue, N.; Tokiyoshi, E.; Takuse, Y.; Arakawa, Y.; Hidaka, Y.; Iwatani, Y. DICER and DROSHA gene expression and polymorphisms in autoimmune thyroid diseases. Autoimmunity 2016, 49, 514–522. [Google Scholar] [CrossRef]
  49. Luna, C.; Li, G.; Qiu, J.; Epstein, D.L.; Gonzalez, P. Role of miR-29b on the regulation of the extracellular matrix in human trabecular meshwork cells under chronic oxidative stress. Mol. Vis. 2009, 15, 2488–2497. [Google Scholar]
  50. Chakraborty, M.; Sahay, P.; Rao, A. Primary Human Trabecular Meshwork Model for Pseudoexfoliation. Cells 2021, 10, 3448. [Google Scholar] [CrossRef]
  51. Sharma, S.; Chataway, T.; Klebe, S.; Griggs, K.; Martin, S.; Chegeni, N.; Dave, A.; Zhou, T.; Ronci, M.; Voelcker, N.H.; et al. Novel protein constituents of pathological ocular exfoliation syndrome deposits identified with mass spectrometry. Mol. Vis. 2018, 24, 801–817. [Google Scholar] [PubMed]
  52. Wolosin, J.M.; Ritch, R.; Bernstein, A.M. Is Autophagy Dysfunction a Key to Exfoliation Glaucoma? J. Glaucoma 2018, 27, 197–201. [Google Scholar] [CrossRef] [PubMed]
  53. Rao, A.; Sahay, P.; Chakraborty, M.; Prusty, B.K.; Srinivasan, S.; Jhingan, G.D.; Mishra, P.; Modak, R.; Suar, M. Switch to Autophagy the Key Mechanism for Trabecular Meshwork Death in Severe Glaucoma. Clin. Ophthalmol. 2021, 15, 3027–3039. [Google Scholar] [CrossRef]
  54. De Juan-Marcos, L.; Escudero-Domínguez, F.A.; Hernández-Galilea, E.; Cruz-González, F.; Follana-Neira, I.; González-Sarmiento, R. Investigation of Association between Autophagy-Related Gene Polymorphisms and Exfoliation Syndrome and Exfoliation Glaucoma in a Spanish Population. Semin. Ophthalmol. 2018, 33, 361–366. [Google Scholar] [CrossRef] [PubMed]
  55. Want, A.; Gillespie, S.R.; Wang, Z.; Gordon, R.; Iomini, C.; Ritch, R.; Wolosin, J.M.; Bernstein, A.M. Autophagy and Mitochondrial Dysfunction in Tenon Fibroblasts from Exfoliation Glaucoma Patients. PLoS ONE 2016, 11, e0157404. [Google Scholar] [CrossRef]
  56. Chistiakov, D.A.; Sobenin, I.A.; Revin, V.V.; Orekhov, A.N.; Bobryshev, Y.V. Mitochondrial aging and age-related dysfunction of mitochondria. BioMed Res. Int. 2014, 2014, 238463. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  57. Manickam, A.H.; Michael, M.J.; Ramasamy, S. Mitochondrial genetics and therapeutic overview of Leber’s hereditary optic neuropathy. Indian J. Ophthalmol. 2017, 65, 1087–1092. [Google Scholar]
  58. Tanwar, M.; Dada, T.; Sihota, R.; Dada, R. Mitochondrial DNA analysis in primary congenital glaucoma. Mol. Vis. 2010, 16, 518–533. [Google Scholar]
  59. Izzotti, A.; Longobardi, M.; Cartiglia, C.; Sacca, S.C. Mitochondrial damage in the trabecular meshwork occurs only in primary open-angle glaucoma and in pseudoexfoliative glaucoma. PLoS ONE 2011, 6, e14567. [Google Scholar] [CrossRef] [Green Version]
  60. Porter, K.; Nallathambi, J.; Lin, Y.; Liton, P.B. Lysosomal basification and decreased autophagic flux in oxidatively stressed trabecular meshwork cells: Implications for glaucoma pathogenesis. Autophagy 2013, 9, 581–594. [Google Scholar] [CrossRef] [Green Version]
  61. Liton, P.B.; Lin, Y.; Gonzalez, P.; Epstein, D.L. Potential role of lysosomal dysfunction in the pathogenesis of primary open angle glaucoma. Autophagy 2009, 5, 122–124. [Google Scholar] [CrossRef] [Green Version]
  62. Abu-Amero, K.K.; Morales, J.; Bosley, T.M. Mitochondrial abnormalities in patients with primary open-angle glaucoma. Investig. Ophthalmol. Vis. Sci. 2006, 47, 2533–2541. [Google Scholar] [CrossRef] [PubMed]
  63. Sundaresan, P.; Simpson, D.A.; Sambare, C.; Duffy, S.; Lechner, J.; Dastane, A.; Dervan, E.W.; Vallabh, N.; Chelerkar, V.; Deshpande, M.; et al. Whole-mitochondrial genome sequencing in primary open-angle glaucoma using massively parallel sequencing identifies novel and known pathogenic variants. Genet. Med. Off. J. Am. Coll. Med. Genet. 2015, 17, 279–284. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Abu-Amero, K.K.; Bosley, T.M.; Morales, J. Analysis of nuclear and mitochondrial genes in patients with exfoliation glaucoma. Mol. Vis. 2008, 14, 29–36. [Google Scholar]
  65. Sirohi, K.; Swarup, G. Defects in autophagy caused by glaucoma-associated mutations in optineurin. Exp. Eye Res. 2016, 144, 54–63. [Google Scholar] [CrossRef]
  66. Bosley, T.M.; Hellani, A.; Spaeth, G.L.; Myers, J.; Katz, L.J.; Moster, M.R.; Milcarek, B.; Abu-Amero, K.K. Down-regulation of OPA1 in patients with primary open angle glaucoma. Mol. Vis. 2011, 17, 1074–1079. [Google Scholar]
  67. Davies, V.; Votruba, M. Focus on molecules: The OPA1 protein. Exp. Eye Res. 2006, 83, 1003–1004. [Google Scholar] [CrossRef]
  68. Lenaers, G.; Reynier, P.; Elachouri, G.; Soukkarieh, C.; Olichon, A.; Belenguer, P.; Baricault, L.; Ducommun, B.; Hamel, C.; Delettre, C. OPA1 functions in mitochondria and dysfunctions in optic nerve. Int. J. Biochem. Cell Biol. 2009, 41, 1866–1874. [Google Scholar] [CrossRef] [Green Version]
  69. Singh, L.N.; Crowston, J.G.; Lopez Sanchez, M.I.G.; Van Bergen, N.J.; Kearns, L.S.; Hewitt, A.W.; Yazar, S.; Mackey, D.A.; Wallace, D.C.; Trounce, I.A. Mitochondrial DNA Variation and Disease Susceptibility in Primary Open-Angle Glaucoma. Investig. Ophthalmol. Vis. Sci. 2018, 59, 4598–4602. [Google Scholar] [CrossRef]
  70. Coca-Prados, M. The blood-aqueous barrier in health and disease. J. Glaucoma 2014, 23, S36–S38. [Google Scholar] [CrossRef]
  71. Bill, A. The blood-aqueous barrier. Trans. Ophthalmol. Soc. UK 1986, 105, 149–155. [Google Scholar] [PubMed]
  72. Küchle, M.; Vinores, S.A.; Mahlow, J.; Green, W.R. Blood-aqueous barrier in exfoliation syndrome: Evaluation by immunohistochemical staining of endogenous albumin. Graefe’s Arch. Clin. Exp. Ophthalmol. 1996, 234, 12–18. [Google Scholar] [CrossRef] [PubMed]
  73. Wiggs, J.L.; Pawlyk, B.; Connolly, E.; Adamian, M.; Miller, J.W.; Pasquale, L.R.; Haddadin, R.I.; Grosskreutz, C.L.; Rhee, D.J.; Li, T. Disruption of the blood-aqueous barrier and lens abnormalities in mice lacking lysyl oxidase-like 1 (LOXL1). Investig. Ophthalmol. Vis. Sci. 2014, 55, 856–864. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  74. Küchle, M.; Nguyen, N.X.; Hannappel, E.; Naumann, G.O. The blood-aqueous barrier in eyes with exfoliation syndrome. Ophthalmic Res. 1995, 27, 136–142. [Google Scholar] [CrossRef] [PubMed]
  75. Yavrum, F.; Elgin, U.; Kocer, Z.A.; Fidanci, V.; Sen, E. Evaluation of aqueous humor and serum clusterin levels in patients with glaucoma. BMC Ophthalmol. 2021, 21, 25. [Google Scholar] [CrossRef]
  76. Doudevski, I.; Rostagno, A.; Cowman, M.; Liebmann, J.; Ritch, R.; Ghiso, J. Clusterin and complement activation in exfoliation glaucoma. Investig. Ophthalmol. Vis. Sci. 2014, 55, 2491–2499. [Google Scholar] [CrossRef] [Green Version]
  77. Zenkel, M.; Kruse, F.E.; Jünemann, A.G.; Naumann, G.O.; Schlötzer-Schrehardt, U. Clusterin deficiency in eyes with exfoliation syndrome may be implicated in the aggregation and deposition of pseudoexfoliative material. Investig. Ophthalmol. Vis. Sci. 2006, 47, 1982–1990. [Google Scholar] [CrossRef]
  78. Yildirim, Z.; Yildirim, F.; Uçgun, N.I.; Sepici-Dinçel, A. The role of the cytokines in the pathogenesis of exfoliation syndrome. Int. J. Ophthalmol. 2013, 6, 50–53. [Google Scholar]
  79. Kondkar, A.; Azad, T.A.; Almobarak, F.; Kalantan, H.; Al-Obeidan, S.A.; Abu-Amero, K.K. Elevated levels of plasma tumor necrosis factor alpha in patients with exfoliation glaucoma. Clin. Ophthalmol. 2018, 12, 153–159. [Google Scholar] [CrossRef] [Green Version]
  80. Eraslan, N.; Elgin, U.; Şen, E.; Kilic, A.; Yilmazbas, P. Comparison of total/active ghrelin levels in primary open angle glaucoma; exfoliation glaucoma and exfoliation syndrome. Int. J. Ophthalmol. 2018, 11, 823–827. [Google Scholar]
  81. Bleich, S.; Roedl, J.; Von Ahsen, N.; Schlötzer-Schrehardt, U.; Reulbach, U.; Beck, G.; Kruse, F.E.; Naumann, G.O.; Kornhuber, J.; Jünemann, A.G. Elevated homocysteine levels in aqueous humor of patients with exfoliation glaucoma. Am. J. Ophthalmol. 2004, 138, 162–164. [Google Scholar] [CrossRef] [PubMed]
  82. Kuroki, M.; Voest, E.E.; Amano, S.; Beerepoot, L.V.; Takashima, S.; Tolentino, M.; Kim, R.Y.; Rohan, R.M.; Colby, K.A.; Yeo, K.T.; et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J. Clin. Investig. 1996, 98, 1667–1675. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  83. Borazan, M.; Karalezli, A.; Kucukerdonmez, C.; Bayraktar, N.; Kulaksizoglu, S.; Akman, A.; Akova, Y.A. Aqueous humor and plasma levels of vascular endothelial growth factor and nitric oxide in patients with exfoliation syndrome and exfoliation glaucoma. J. Glaucoma 2010, 19, 207–211. [Google Scholar] [CrossRef]
  84. Aiello, L.P.; Northrup, J.M.; Keyt, B.A.; Takagi, H.; Iwamoto, M.A. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch. Ophthalmol. 1995, 113, 1538–1544. [Google Scholar] [CrossRef] [PubMed]
Cimb 44 00078 g001 550
Figure 1. (a) Retroillumination showing peripheral granular exfoliative deposits, (b) exfoliative deposits (indicated by blue arrow) over the pupil with diffuse stromal iris atrophy, (c) diagrammatic depiction of the role of TGF-β1 in various cell processes and the changes that occur as the disease progresses from normal (control) to exfoliation syndrome (XFS) to exfoliation glaucoma (XFG).TGF-β1—transforming growth factor-beta1; BAB—blood–aqueous barrier; BRB—blood–retina barrier; VEGF—vascular endothelial growth factor; ROS—reactive oxygen species; ECM—extracellular matrix. Biorender. Available online: https://biorender.com/ (accessed on 17 February 2022).
Figure 1. (a) Retroillumination showing peripheral granular exfoliative deposits, (b) exfoliative deposits (indicated by blue arrow) over the pupil with diffuse stromal iris atrophy, (c) diagrammatic depiction of the role of TGF-β1 in various cell processes and the changes that occur as the disease progresses from normal (control) to exfoliation syndrome (XFS) to exfoliation glaucoma (XFG).TGF-β1—transforming growth factor-beta1; BAB—blood–aqueous barrier; BRB—blood–retina barrier; VEGF—vascular endothelial growth factor; ROS—reactive oxygen species; ECM—extracellular matrix. Biorender. Available online: https://biorender.com/ (accessed on 17 February 2022).
Cimb 44 00078 g001
Table
Table 1. List of miRNAs identified in exfoliation syndrome (XFS) and exfoliation glaucoma (XFG) and their functions.
Table 1. List of miRNAs identified in exfoliation syndrome (XFS) and exfoliation glaucoma (XFG) and their functions.
miRNAAccession NumberFunctionReference
hsa-miR-125bMIMAT0000423Directly targets P53. TP53 gene is closely associated with lens epithelial cell apoptosis. (validated)Drewry et al., 2018
hsa-miR-6722-3pMIMAT0025854Involved in mitogen-activated protein kinase (MAPK) signaling pathway; forkhead box, class O (FOXO) signaling pathway; and regulation of actin cytoskeleton. (predicted)Kosior-Jarecka et al., 2021
hsa-miR-184MIMAT0000454Involved mainly in response to hypoxia, cardiovascular system development, and apoptosis. Mutations in hsa-miR-184, which were linked with lens/corneal dystrophy and blindness. (predicted)Kosior-Jarecka et al., 2021
hsa-miR-4634MIMAT0019691Is a validated regulator of VAV3, whose deficiency in mice was associated with an ocular phenotype similar to glaucoma, including elevated IOP, selective loss of retinal ganglion cells, and optic nerve head cupping. (validated)Kosior-Jarecka et al., 2021
hsa-miR-1260bMIMAT0015041May play a protective role in the course of glaucomatous neuropathy. Is also an essential regulator of vascular smooth muscle cell proliferation in response to hypoxia. (predicted)Kosior-Jarecka et al., 2021
miR-122-5pMIMAT0000421Controls TGF-β1, protein binding, and ECM-related processes. Has been shown to regulate opteneuin pathway. (validated)Rao et al., 2020; Drewryet al., 2018
hsa-miR-124-3pMIMAT0000422Controls TGF-β1, protein binding, and ECM-related processes. (predicted)Rao et al., 2020
hsa-miR-424-5pMIMAAT0001341Is a tumor-suppressive miRNA. It regulates proliferation and invasion. It can also inhibit cell migration and epithelial–mesenchymal transition. (predicted)Rao et al., 2020
hsa-miR-30c-5pMIMAT0000244Directly targets MAPK1 to regulate proliferation and migration. Negatively regulates protein secretion. (validated)Rao et al., 2020
hsa-miR-96-5pMIMAT0000095Inhibits apoptosis by targeting caspase-9 gene. (validated)Rao et al., 2020
hsa-miR-142-5pMIMAT0000433Acts as a negative regulator in TGF-β pathway by targeting SMAD3 and suppresses TGF-β-induced growth inhibition. (validated)Rao et al., 2020
hsa-miR-9-5pMIMAT0000441Plays a role in growth, invasion, migration, and epithelial–mesenchymal transition. Negatively regulates cell adhesion and janus kinase–signal transducer and activator of transcription(JAK/STAT) pathway. (validated)Rao et al., 2020
hsa-miR-143-3pMIMAT0000435It regulates proliferation, migration, and invasion. Negativelyregulates angiogenesis, actin cytoskeleton organization, regulation of blood vessel and endothelial cell proliferation. (validated)Rao et al., 2020
hsa-miR-302a-3pMIMAT0000684Post-transcriptional gene silencing. Overexpression can inhibit proliferation and promote apoptosis. May modulate epithelial–mesenchymal transition. (validated)Rao et al., 2020
hsa-miR-223-3pMIMAT00003280Plays a protective role against endothelial injury, inhibits cell proliferation and migration, and negatively regulates inflammatory response and necrotic cell death. (validated)Rao et al., 2020
hsa-miR-630MIMAT0003299Involved in the regulation of apoptosis. (predicted)Drewryet al., 2018
hsa-miR-451aMIMAT0001631Associated with cell proliferation, migration, and apoptosis through targeting activating transcription factor 2 (ATF2) signaling pathway. It can inhibit hepatic gluconeogenesis and alleviate hyperglycemia. (predicted)Drewryet al., 2018
has-miR-637MIMAT0003307Involved in tryosine metabolism and endocytosis. (predicted)Hindle, 2019
hsa-miR-4725-3pMIMAT0019844Involved in MAPK signaling pathway, p53 signaling pathway, and regulation of actin cytoskeleton. (predicted)Hindle, 2019
hsa-miR-433-3pMIMAT0001627Involved in MAPK signaling pathway, p53 signaling pathway, FOXO signaling pathway, and regulation of actin cytoskeleton. (predicted)Hindle, 2019
hsa-miR-302d-3pMIMAT0000718Involved in tryosine metabolism and endocytosis. (predicted)Drewry et al., 2018
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Chakraborty, M.; Rao, A. Alternate Causes for Pathogenesis of Exfoliation Glaucoma, a Multifactorial Elastotic Disorder: A Literature Review. Curr. Issues Mol. Biol. 2022, 44, 1191-1202. https://doi.org/10.3390/cimb44030078

AMA Style

Chakraborty M, Rao A. Alternate Causes for Pathogenesis of Exfoliation Glaucoma, a Multifactorial Elastotic Disorder: A Literature Review. Current Issues in Molecular Biology. 2022; 44(3):1191-1202. https://doi.org/10.3390/cimb44030078

Chicago/Turabian Style

Chakraborty, Munmun, and Aparna Rao. 2022. "Alternate Causes for Pathogenesis of Exfoliation Glaucoma, a Multifactorial Elastotic Disorder: A Literature Review" Current Issues in Molecular Biology 44, no. 3: 1191-1202. https://doi.org/10.3390/cimb44030078

Article Metrics

Back to TopTop